HDAC3 and cancer: For patient su008, entinostat, a benzamide histone deacetylase inhibitor targeting HDAC1 and HDAC3 treated as monotherapy [79] or combinatorial drug together with immunotherapy to various cancers [80, 81], was ranked 4th in comboSC prediction results as a drug that can be paired with immunotherapy.